Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron Deal Offers Novartis Entry Into Vaccine Business

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis seeks to acquire remaining 57.8% of Chiron it does not already own with an all-cash bid of $4.5 bil.

You may also be interested in...



Novartis Willing To “Walk Away” From Chiron Bid

Chiron’s business is “strategically attractive,” but the company faces several challenges, particularly in vaccine manufacturing, Novartis CEO Vasella says.

Novartis Willing To “Walk Away” From Chiron Bid

Chiron’s business is “strategically attractive,” but the company faces several challenges, particularly in vaccine manufacturing, Novartis CEO Vasella says.

Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer

A $4.5 bil. cash offer from Novartis for an outstanding 57.8% stake in Chiron is “inadequate,” according to Chiron’s independent directors.

Related Content

Topics

UsernamePublicRestriction

Register

PS062856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel